

UC San Diego

UC San Diego Previously Published Works

Title

Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation

Permalink

<https://escholarship.org/uc/item/3xs321vw>

Journal

Nature Cell Biology, 25(2)

ISSN

1465-7392

Authors

Wu, Chengsheng
Rakhshandehroo, Taha
Wettersten, Hiromi I
[et al.](#)

Publication Date

2023-02-01

DOI

10.1038/s41556-022-01055-y

Peer reviewed



Published in final edited form as:

Nat Cell Biol. 2023 February ; 25(2): 309–322. doi:10.1038/s41556-022-01055-y.

Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumor initiation

Chengsheng Wu¹, Taha Rakhshandehroo^{1,2}, Hiromi I. Wettersten¹, Alejandro Campos¹, Tami Von Schalscha¹, Shashi Jain¹, Ziqi Yu¹, Jiali Tan¹, Evangeline Mose³, Betzaira G. Childers³, Andrew M. Lowy³, Sara M. Weis¹, David A. Cheresch^{1,*}

¹Department of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California, United States of America.

²Current address: Department of Radiology, Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts, United States of America.

³Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California, San Diego, La Jolla, California, United States of America.

Abstract

Defining drivers of tumor initiation can provide opportunities to control cancer progression. Here, we report that lysophosphatidic acid receptor 4 (LPAR4) becomes transiently upregulated on pancreatic cancer cells exposed to environmental stress or chemotherapy where it promotes stress tolerance, drug resistance, self-renewal, and tumor initiation. Pancreatic cancer cells gain LPAR4 expression in response to stress by downregulating a tumor suppressor, miR-139-5p. Even in the absence of exogenous LPA, LPAR4-expressing tumor cells display an enrichment of extracellular matrix (ECM) genes that are established drivers of cancer stemness. Mechanistically, upregulation of fibronectin via a LPAR4/AKT/CREB axis is indispensable for LPAR4-induced tumor initiation and stress tolerance. Moreover, ligation of this fibronectin containing matrix via integrins $\alpha 5\beta 1$ or $\alpha V\beta 3$ can transfer stress tolerance to LPAR4-negative cells. Therefore, stress- or drug-induced LPAR4 enhances cell-autonomous production of a fibronectin-rich ECM, allowing cells to survive “isolation stress” and compensate for the absence of stromal-derived factors by creating their own tumor-initiating niche.

Introduction

Tumor-initiating cells (TIC) are significant contributors to tumor growth, recurrence, and metastatic spread by virtue of their capacity to overcome various forms of stress^{1, 2}. Such

*Corresponding author: dcheresh@health.ucsd.edu.

Author contributions

C.W., S.W., and D.C. conceived, designed, and wrote the manuscript. C.W. performed all the experiments with the exception of: some of the in vitro experiments performed by T.R., T.S., S.J., and J.T.; the in vivo experiments and data analysis assisted by H.W., Z.Y., and T.R.; and patient-derived xenograft cells were generated by E.M., B.C., and A.L. A.C. assisted the RNA-seq data analysis.

Competing interests

The authors declare no competing interests.

features are not only derived from intrinsic stem-like traits but can be influenced by tumor stroma-derived immune cell factors within a cancer stem cell (CSC) niche³. One such factor is lysophosphatidic acid⁴, a bioactive lipid that regulates cell fate transitions for a variety of stem cell types, including CSCs^{5, 6}.

We are particularly interested in how TIC properties may fluctuate in response to external cues⁷, such as changes in vascularization that impact oxygenation and access to nutrients, or application of therapeutic pressures designed to eliminate vulnerable populations of tumor cells. At the earliest stage of tumor formation or during seeding of metastatic cells in distant organs, individual tumor cells must overcome the challenging consequences of isolation-induced stresses such as hypoxia, nutrient deprivation, and oxidative stress, while compensating for the loss of matrix adhesion, cell-cell contact, or immune cell and stromal-produced survival factors^{8, 9}. While TIC may inherently possess resistance to such stresses, we considered whether non-TIC may undergo adaptive reprogramming to overcome isolation stress and thereby gain tumor initiating properties.

Pancreatic cancer is a lethal cancer that is notoriously resilient to therapy due in part to poor vascularization and dense stroma in the tumor microenvironment¹⁰. LPA and the enzyme that produces LPA, autotaxin, are particularly enriched in pancreatic cancer^{11, 12}, which can exploit LPA produced by neighboring pancreatic stellate cells to drive ductal adenocarcinoma (PDAC) growth in vivo¹². Functions of the six G-protein coupled LPA receptors (LPAR1–6) do not appear to overlap in pancreatic cancer cells. LPAR1 promotes cell migration and metastasis^{13, 14}, while LPAR2 suppresses migration¹⁵. Interestingly, LPAR4 suppresses mobility in PANC1 cells¹⁶, but is also necessary for cardiac dedifferentiation and heart tissue repair¹⁷, suggesting a context-dependent role.

Here, we discovered that LPAR4 becomes upregulated by the stress-induced loss of a tumor suppressive microRNA (miRNA) and is capable of conferring TIC properties, stress tolerance, and drug resistance. Mechanistically, LPAR4 expression endows solitary tumor cells with the ability to create their own fibronectin-containing niche to support tumor initiation. The molecular basis for this adaptive reprogramming mechanism may provide therapeutic opportunities to slow pancreatic cancer progression and sensitize tumors to therapeutic intervention.

Results

Pancreatic cancer cells upregulate LPAR4 in response to stress

Tumor cells must overcome various stressors during tumor initiation and progression, including hypoxia, nutrient stress, loss of adhesion, oxidative stress, and therapeutic stress. Given the role of autotaxin/LPA in pancreatic cancer progression¹⁸, we asked whether one or more LPA receptor(s) are linked to tumor initiation. To create tumor growth conditions that would selectively favor the survival of TIC in vivo, nu/nu mice received a subcutaneous injection of 300 pancreatic cancer cells, a cell number we established produces palpable tumors in approximately 50% of the injection sites after 14 days (Fig. 1a). Compared to an injection of 1 million cells resulting in tumor growth at all injection sites, we propose that tumors formed from a limiting number of cells creates a state of “isolation stress” that

highlights the contribution of tumor initiating and/or self-renewing cells. Among the six LPA receptors, only LPAR4 was enriched in isolation-stressed tumors formed by 300 cells (Fig. 1a–1b). Interestingly, *LPAR4* expression was significantly higher in early-stage (Day 20) lesions vs. established (Day 35) tumors (Fig. 1c), indicating that *LPAR4* is transiently expressed when tumor cells are experiencing “isolation stress” but downregulated as tumors become established. Compared with cells grown in 2D adherent culture conditions, *LPAR4* mRNA was highly enriched in the self-renewing cells that form secondary tumor spheres (Fig. 1d). Thus, *LPAR4* is upregulated under in vitro and in vivo conditions that enrich for TIC.

We next considered if LPAR4 upregulation represents a general mechanism that pancreatic cancer cells use to overcome the effects of cellular stresses encountered during tumor initiation. Whereas the expression of each *LPAR* in the absence of stress shows heterogeneity among individual pancreatic cancer cell lines (Extended Data Fig. 1a), subjecting cells to nutrient stress in combination with non-adherent culture conditions selectively upregulated *LPAR4* mRNA expression across all cell lines tested (Extended Data Fig. 1b). *LPAR4* mRNA and protein expression was selectively induced in cells exposed to various stresses (Extended Data Fig. 1c) or sublethal doses of chemotherapy (Fig. 1e–g and Extended Data Fig. 1d–e). To investigate whether therapeutic stress induces *LPAR4* expression in vivo, we orthotopically implanted 1–2mm³ patient-derived xenograft (PDX) tumor fragments into the pancreas of NSG mice. Once each tumor reached 50–100mm³ as evaluated by ultrasound, mice received twice weekly injections of either vehicle or 100 mg/kg gemcitabine. After 6 weeks of treatment, *LPAR4* expression was significantly higher in tumors from gemcitabine-treated mice compared to the control group (Fig. 1h). Together, these findings indicate that *LPAR4* is a stress responsive gene in pancreatic cancer cells.

LPAR4 is necessary and sufficient to drive tumor initiation

For the TNMplot public dataset¹⁹, *LPAR4* gene expression was significantly higher in pancreatic adenocarcinoma (PAAD) than in normal pancreas (Fig. 2a). While normal pancreas cores were negative, 6 out of 15 PDAC cores showed a relatively high level *LPAR4* expression (Extended Data Fig. 2a). Clinically, the significance of *LPAR4*, analysis of the TCGA PAAD dataset revealed that high *LPAR4* mRNA expression significantly correlated with a shorter relapse free survival (RFS, $P=0.017$), with a similar trend for overall survival ($P=0.18$) (Fig. 2b), indicating high *LPAR4* expression is associated with worse outcomes in pancreatic adenocarcinoma patients.

To evaluate the biological significance of *LPAR4*, we stably knocked down *LPAR4* using shRNA (sh-R4) or ectopically expressed *LPAR4* (+R4) in multiple pancreatic cancer cell lines and patient-derived xenograft models (Extended Data Fig. 2b). Using a limiting dilution assay to gauge the contribution of *LPAR4* to subcutaneous tumor initiation in vivo, TIC frequency was reduced by *LPAR4* knockdown and enhanced by ectopic *LPAR4* expression (Fig. 2c and Supplementary Table 1). Using an orthotopic limiting dilution tumor initiation assay with noninvasive bioluminescence imaging, we similarly found that TIC frequency was 90% lower for cells with *LPAR4* knockdown (Fig. 2d, Supplementary Table 2, and Extended Data Fig. 2c). While manipulation of *LPAR4* expression had no effect

on in vitro growth in the absence of stress (Extended Data Fig. 2d–e) or tumor growth in vivo (Extended Data Fig. 2f), ectopic expression of *LPAR4* could help cells to overcome the challenge of isolation stress imposed during tumor sphere formation in 3D culture (Fig. 2e). Similarly, forms of stress that induce *LPAR4* expression (hydrogen peroxide, serum deprivation) also enhanced tumor sphere formation in an *LPAR4*-dependent manner (Fig. 2f). As an additional readout for stress tolerance, *LPAR4* was both necessary and sufficient to mitigate the accumulation of mitochondrial superoxide (MitoSOX) in cells challenged with serum deprivation stress (Fig. 2g–h). In contrast, knockdown of *LPAR1*, a constitutively expressed LPAR on Colo-357 pancreatic cancer cells (Extended Data Fig. 1a and Extended Data Fig. 2g), equally impaired cell growth in both 2D and 3D (Extended Data Fig. 2h), suggesting that LPAR1 plays a more generalized role in cell survival or proliferation. Together, these findings demonstrate that pancreatic cancer cells can overcome the growth limiting conditions during tumor initiation and isolation stress by upregulating *LPAR4*.

Stress suppresses miR-139-5p to release a brake on LPAR4

miRNAs regulate gene expression allowing reprogramming in response to stress or injury²⁰ and contribute to the function of stem-like cells in pancreatic²¹ and other cancers²². To determine if a miRNA may account for the upregulation of *LPAR4* in response to stress, we used multiple miRNA-target prediction tools to generate a list of putative LPAR4-targeting miRNAs and then evaluated how these correspond to survival for the TCGA PAAD dataset. The top hit from this approach was miR-139-5p, for which the median survival of the high cohort (50.1 months) greatly exceeded that for the low cohort (19.9 months) (Supplementary Table 3 and Fig. 3a). Considering that miR-139-5p had been identified as a tumor suppressor in pancreatic cancer²³, and since hsa-miR-139-5p was predicted to recognize an 8mer binding sequence on the 3'UTR of the *LPAR4* promoter (Fig. 3b), we considered how stress would impact miR-139-5p. Remarkably, multiple stressors upregulated *LPAR4* and downregulated miR-139-5p, while another miRNA predicted to bind *LPAR4* (miR-138-5p) was not stress-responsive (Fig. 3c). Additionally, self-renewing cells (i.e., secondary spheres) that were enriched for *LPAR4* mRNA expression showed a significantly lower level of miR-139-5p, but not miR-138-5p, compared with cells grown under 2D conditions (Fig. 3d). Manipulation of *LPAR4* did not alter miR-139-5p levels (Extended Data Fig. 3a), indicating that miR-139-5p is not a downstream target of *LPAR4*.

Cells were transfected with a miR-139-5p mimic to counteract the downregulation of miR-139-5p during stress. The miR-139-5p mimic prevented hypoxia induced expression of *LPAR4* (Fig. 3e–f) while the anti-miR-139-5p inhibitor was sufficient to increase *LPAR4* expression in the absence of stress (Fig. 3g and Extended Data Fig. 3b), as well as a known miR-139-5p target, *FOXO1* (ref. ^{24, 25}). Using a LPAR4–3'UTR luciferase reporter assay, we observed miR-139-5p direct binding to the LPAR4–3'UTR (Extended Data Fig. 3c), which was decreased by the miR-139-5p mimic and increased by anti-miR-139-5p (Fig. 3h). In unstressed cells, *LPAR4* expression and tumorsphere formation that was increased by anti-miR-139-5p could be reversed by shRNA-mediated knockdown of *LPAR4* (Fig. 3i and Extended Data Fig. 3d), while ectopic *LPAR4* could rescue the inhibitory effect of the miR-139-5p mimic on tumor sphere formation (Fig. 3j). Thus, the effect of miR-139-5p

on tumorsphere formation is primarily due to its regulation of *LPAR4*. In support of this, among several gene targets of miR-139-5p in tumor cells, *LPAR4* was the most consistently decreased by the miR-139-5p mimic (Extended Data Fig. 3e). Together, these findings indicate that *LPAR4* expression depends on the stress-inducible loss of miR-139-5p expression, revealing the existence of a stress-response pathway that pancreatic cancer cells can use to overcome isolation stress.

LPAR4 gene signature includes ECM-related genes

To further investigate how pancreatic cancer cells utilize LPAR4 to gain stem-like properties, patient-derived 79E pancreatic cancer cells with stable ectopic expression of *LPAR4* (+R4) or control cells were treated with or without the canonical LPAR4 ligand, LPA, and then harvested for RNA-seq analysis. As expected, control cells responded to LPA by upregulating a cluster of differentially expressed genes (DEGs) (gene cluster 1) that promote gene ontology (GO) terms such as cell proliferation, growth factor activity, cell-cell signaling, and signal transduction (Fig. 4a). To our surprise, a set of genes (gene cluster 3) were differentially expressed in +R4 cells compared with +EV cells and independent of LPA, notably including multiple GO terms related to extracellular matrix (ECM) proteins and organization (Fig. 4a). The genes in this cluster were validated in 4 paired cell lines using individual qPCR assays (Fig. 4b and Extended Data Fig. 4a). Thus, cells that upregulate *LPAR4* gain a subset of pro-tumor functions regardless of their exposure to LPA, supporting the notion that LPAR4 allows cells to overcome isolation stress during tumor initiation when there is limited access to LPA derived from vascular, stromal, or immune cells.

We next performed an overlap analysis to identify DEGs in common between 79E+R4 cells and LPAR4-high patient tumors from the TCGA PAAD dataset (Fig. 4c and Supplementary Table 4). Upregulated DEGs included several ECM genes with documented roles as contributors to pancreatic cancer progression, such as fibronectin (*FN1*)²⁶. DEGs that were lower in LPAR4+ cells and tumors included the pancreatic lineage marker *FOXA3* (ref.²⁷), suggesting that *LPAR4* expression was associated with an immature or dedifferentiated phenotype. Notably, the upregulated DEGs were associated with positive hazard ratios (indicating poor relapse free survival) while the downregulated DEGs were associated with negative hazard ratios (Supplementary Table 4). All hazard ratios achieved statistical significance ($P < 0.05$) except as indicated, indicating the genes identified as part of the LPAR4 gene signature play a role in human pancreatic cancer progression.

In line with the observation that the pro-tumor gene signature regulated by LPAR4 does not require exogenous LPA treatment, ectopic expression of *LPAR4* allowed cells grown in media containing either charcoal-stripped serum (to deplete bioactive lipids including LPA) or no serum to tolerate higher levels of stress induced by H₂O₂ or gemcitabine (Fig. 4d and Extended Data Fig. 4b). Similarly, exogenous LPA was not required for the ability of ectopic *LPAR4* to promote 3D tumorsphere formation in methylcellulose or suspension culture (Fig. 4e and Extended Data Fig. 4c). Accordingly, expression of the antioxidant gene *SOD3* was significantly higher in +R4 cells in the absence of LPA (Extended Data Fig. 4d). Interestingly, 34E+R4 cells had significantly enriched expression of the pancreatic

CSC markers *PROM1*, *EPCAM*, and *CD44*, while 79E+R4 cells showed higher expression of *ALDH1A1* (Extended Data Fig. 4d), suggesting the phenotype of +R4 cells overlaps to some extent with CSC populations, and this appears to be LPA independent. Together, these findings indicate pancreatic cancer cells that gain LPAR4 can autonomously produce pericellular matrices and acquire properties of TIC. Notably, this appears to occur even when there is limited access to LPA within the surrounding microenvironment, such as one lacking blood vessels, immune cells, or stromal cells which serve as sources of LPA in pancreatic cancer^{12, 28}.

LPAR4 promotes the cell-autonomous production of FN1

ECM proteins have a profound impact on cancer development and progression²⁹. Among the ECM-related genes upregulated by *LPAR4*, we were especially interested in *FN1* because of its links to cancer stemness and tumor initiation^{30–32}, biological features that are also induced by *LPAR4*. In fact, there was a positive correlation between *LPAR4* and *FN1* mRNA expression for the TCGA PAAD dataset ($P<0.0001$) (Fig. 5a) and orthotopic PDX tumors ($P=0.0180$), while gemcitabine treated PDX tumors expressed high levels of both *LPAR4* and *FN1* (Fig. 5b). As observed for *LPAR4*, *FN1* expression was also significantly higher in PAAD tumors than in normal pancreas (Extended Data Fig. 5a). Importantly, analysis of the TCGA PAAD dataset revealed that high *FN1* expression significantly correlated with lower overall and relapse-free survival (both $P<0.05$) (Fig. 5c).

FN1 has up to 20 distinct isoforms due to alternative splicing, and isoforms that contain the Extra Domain A (EDA) or EDB regions appear to be more tumorigenic³³. Thus, we asked whether LPAR4-induced *FN1* mRNA contains EDA, or EDB, or both domains. As shown in Extended Data Fig. 5b, +R4 cells expressed comparable mRNA levels of *FN1*, *FN1-EDA*, and *FN1-EDB*, suggesting LPAR4-induced *FN1* likely contains both the pro-tumor EDA and EDB domains. As shown for LPAR4 (Fig. 1a), FN1 expression was higher in isolation-stressed tumors formed from the injection of 300 cells compared with those formed by 1 million cells (Fig. 5d). Consistent with the LPAR4 gene signature, +R4 cells showed higher levels of FN1 protein in the absence of exogenous LPA (Fig. 5e–f). In an orthotopic tumor model, there was more abundant FN1 staining in the matrix surrounding Colo-357+R4 tumor cells than for Colo-357+EV tumor cells (Fig. 5g), providing evidence of LPAR4-induced tumor intrinsic FN1 production and deposition in vivo. Furthermore, cells exposed to hypoxia showed increased FN1, and this was prevented by LPAR4 knockdown (Fig. 5h and Extended Data Fig. 5c). These findings indicate that LPAR4 expression changes the phenotype of pancreatic cancer cells, providing them with a cell-autonomous source of pro-tumor FN1, creating a TIC niche to support survival during the earliest stages of tumor formation.

FN1 is indispensable for LPAR4-induced TIC properties

Next, we asked what signaling event(s) activated by LPAR4 drive FN1 expression. cAMP response element-binding protein (CREB) is a known stress-responsive transcription factor that can bind to the *FN1* gene exon1^{34, 35}. Indeed, *LPAR4* knockdown prevented hypoxia-induced FN1 protein expression and CREB phosphorylation at serine 133, an indicator of CREB activity³² (Fig. 6a). In addition, all +R4 cells showed higher CREB activity in the

absence of exogenous LPA (Fig. 6b), suggesting LPAR4 was sufficient to activate CREB. Importantly, treating +R4 cells with CREB siRNA or CREB inhibitor 666–15 resulted in a dramatic decrease of FN1 protein expression (Fig. 6c–d). Using a CREB ChIP-qPCR assay, we detect significantly enriched CREB occupancy on *FN1* exon1 in +R4 cells, relative to +EV cells, in the absence of exogenous LPA (Fig. 6e). Together, these results demonstrate that LPAR4-mediated activation of CREB directly drives the transcription of *FN1* in pancreatic cancer cells.

Using Gene Set Enrichment Analysis (GSEA) to consider kinases known to activate CREB³⁶, we found that AKT signaling was upregulated in +R4 cells in the absence of LPA (Extended Data Fig. 6a). Consistently, all +R4 cells showed relatively high AKT activity, evidenced by p-AKT-S473 (Fig. 6b), and the AKT inhibitor ipatasertib decreased p-CREB-S133 in a dose/time-dependent manner (Extended Data Fig. 6b), supporting the notion that CREB is a *bona fide* substrate of AKT in our cells. Furthermore, blockade of AKT by either siRNA-mediated knockdown or ipatasertib decreased FN1 in +R4 cells (Fig. 6f–g). In this case, p-GSK3 β -S9 inhibition served as a surrogate indicator for the blockade of AKT kinase activity (Fig. 6g). As shown in Extended Data Fig. 6c, *CREB* knockdown resulted in a significant downregulation of several ECM-related genes within the LPAR4 gene signature, including *FN1* and versican (*VCAN*), in both +R4 cell lines. Together, our data demonstrates that stress-induced LPAR4 activates AKT, leading to CREB-mediated transcription of *FN1*.

Not only has fibronectin been linked to cancer progression³³, but it is critical for the creation of a niche that directs stem cells through different fate changes^{37, 38}. FN1 functions as a scaffold for the deposition of other matrix proteins and anchoring of soluble factors, allowing it to promote angiogenesis, metastasis, chemoresistance, and immune evasion in pancreatic cancer^{33, 39, 40}. Given the abundant FN1 expression in +R4 cells, we asked whether this could account for their phenotype. Indeed, *FN1* knockdown significantly reduced *LPAR4*-induced 3D tumorsphere formation and growth advantage in the presence, but not absence, of stress (Fig. 6h and Extended Data Fig. 6d) and significantly increased MitoSOX levels in +R4, but not +EV, cells grown under serum-free conditions (Fig. 6i and Extended Data Fig. 6f). In addition, ectopic expression of *FN1-EDA* significantly induced 3D tumorsphere formation (Fig. 6j). Together, our data indicates that *FN1* is required for LPAR4-dependent stress tolerance and can account for the LPAR4-induced phenotype.

Considering that LPAR4 supports cell-autonomous growth under stressed conditions, we asked if the FN1-containing ECM produced by LPAR4-expressing pancreatic cancer cells could transfer this advantage to cells lacking LPAR4. To do this, +EV or +R4 cells were grown on tissue culture plastic for 72 hours to allow matrix deposition, and then removed to create a cell-free ECM (Fig. 7a). When LPAR4-negative cells were plated in serum-free growth conditions onto ECM deposited by +R4 cells (ECM-R4), they grew significantly faster than when plated on ECM produced by +EV cells (ECM-EV) (Fig. 7b). Of note, cells plated onto ECM-R4, but not ECM-EV, began to form colonies after several days (Fig. 7c and Extended Data Fig. 7a), further suggesting deposited matrix can transfer cell growth advantages from LPAR4-expressing cells to LPAR4-negative cells. Furthermore, LPAR4-

negative cells grown on ECM-R4 became more stress tolerant to H₂O₂ or gemcitabine, and this was negated by *FN1* knockdown (Fig. 7d).

Finally, we show the ability of ECM-R4 to provide stress tolerance could be eliminated by interfering with fibronectin binding to its cell surface receptors, integrins $\alpha 5\beta 1$ or $\alpha v\beta 3$ (Fig. 7e). Thus, FN1 is a critical effector of LPAR4 that supports LPAR4-induced self-sufficiency, and the ability to transfer this to LPAR4-negative cells requires the function of integrin $\alpha 5\beta 1$ and/or $\alpha v\beta 3$. Lastly, to further substantiate the significance of FN1 for the LPAR4-induced tumor initiation advantage, we knocked down *FN1* in both +EV and +R4 cells and performed a tumor initiating assay by injecting 300 cells in mice. As shown in Fig. 7f, *FN1* knockdown in +R4 cells, but not +EV cells, resulted in a significantly decreased tumor take rate *in vivo*, indicating that *FN1* was required for LPAR4-induced tumor initiation. Together, a variety of *in vitro* and *in vivo* assays consistently indicate that FN1 is a critical effector of LPAR4 in pancreatic cancer cells.

In summary, pancreatic cancer cells can overcome isolation stress through the stress-induced suppression of a miRNA that releases a brake on LPAR4 expression, thus activating an AKT/CREB axis allowing a tumor cell to generate a fibronectin containing ECM niche, and thereby promoting a self-sufficient phenotype (Fig. 7g).

Discussion

Evidence is provided that LPAR4 acts as an adaptive response to stress that pancreatic cancer cells exploit to overcome solitary growth conditions encountered during tumor initiation. Established pancreatic tumors feature a dense stroma that supports growth and survival for pancreatic cancer cells in the primary tumor environment by providing cell-cell and cell-matrix adhesion, as well as secreted factors including cytokines, growth factors, and ECM⁴¹. We propose that at the earliest stages of tumor development or metastatic seeding, solitary tumor cells adapt to isolation stress by downregulating miR-139-5p, which releases the brake on *LPAR4* expression.

Aside from *LPAR4*, we did not find any other previously reported miR-139-5p target genes^{42–44} to be stress dependent in our pancreatic cancer cells. This may be because *IGF1R* and *CCNB1* are highly expressed in unstressed conditions, unlike *LPAR4*. While *IGF1R* and *CCNB1* were ~2-fold downregulated by the miR-139-5p mimic in 34E cells, this was not the case for Colo-357 cells (Extended Data Fig. 3f), suggesting potential context dependent interactions.

Upregulating LPAR4 in response to stress allows solitary pancreatic cancer cells to create their own tumor initiating niche by producing ECM proteins. Fibronectin within this matrix, via integrin ligation, supports a self-sufficient state to enable tumor initiation and can transfer this advantage to nearby LPAR4-negative cells (Fig. 7g). Importantly, we show that blocking the ability of cells to utilize this fibronectin matrix with integrin antagonists can reverse the stress tolerance benefit of LPAR4 expression. Considering that tumors that develop drug resistance via upregulation of LPAR4 show enhanced stress tolerance and tumor initiation, targeting the LPAR4/AKT/CREB pathway or disrupting the integrin/FN1

interaction might not only reduce tumor drug resistance, but could ultimately delay disease progression by suppressing tumor initiation at metastatic sites.

Our gene expression analysis highlights functions for LPAR4 that do not require LPA, suggesting this mechanism to overcome stress represents a non-canonical role for an LPA receptor that is ligand-independent and stress-inducible. In “unstressed” states, cells do not require LPAR4-FN1-integrin signaling when sufficient growth support can be obtained from other cell-cell and cell-matrix interactions, along with the growth factors, cytokines, soluble FN1, and vitronectin provided by fetal bovine serum (FBS). The fact that *LPAR4* expression is undetectable in cells grown in such states may explain why LPAR4 has not yet been appreciated as a stress-inducible contributor to pancreatic cancer.

In a more general context, our work highlights an opportunity to explore additional functions for cell surface proteins with defined roles as “receptors”. LPAR4 might represent a larger family of proteins that can be hijacked by tumor cells to overcome the unfavorable growth conditions encountered during phases of tumor progression that require a self-sufficient phenotype. For example, our previous studies revealed that integrin $\alpha v \beta 3$ functions in a non-ligated state to promote stemness, tumor initiation, and drug resistance in cancer cells^{45–48}. Ultimately, therapeutic agents that block the function of LPAR4 and other receptors enriched on TIC may be overlooked when evaluated by their capacity to halt the growth of well-established primary tumors. Instead, such agents may have an alternative use to limit therapeutic resistance, disease relapse, or metastasis by preventing tumor cells from gaining the self-sufficient phenotype that tumor cells exploit to achieve tumor initiation and spread to distant sites.

Methods

All experiments conform to the relevant regulatory standards and animal studies were conducted under protocol S05018 and S09158, approved by the University of California San Diego Institutional Animal Care protocol and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Reagents, chemicals, and antibodies.

Lysophosphatidic acid (18:1) (Avanti Polar Lipids, Alabaster, AL, #857130) was diluted to 5mM in dH₂O, sonicated at 37°C for 15 mins, and used fresh. The CellTiter-Glo kit (Promega, Madison, WI, #G7573) was used to measure cell viability. Gemcitabine HCl (#S1149), Paclitaxel (NSC 125973) and Hydrogen peroxide (H₂O₂) were purchased from Selleck Chem (Houston, TX) and Thermo Fisher Scientific (H325–100), respectively. Charcoal: Dextran stripped Fetal Bovine Serum (FBS) was purchased from GeminiBio (#100–119). Ipatasertib (GDC-0068, HY-15186) and 666–15 (HY-101120) were purchased from MedChemExpress (Monmouth Junction, NJ). Primary antibodies used in this study included: LPAR4 (Proteintech, #22165–1-AP, 1:1000 for western blots), LPAR4 (Thermo Fisher, #PA5–49727, 1:50 for immunohistochemistry), Vinculin (Santa Cruz Biotechnology, #sc-25336, H-10, 1:5000 for western blots), GAPDH (CST, #5174, D16H11, 1:3000 for western blots), β -actin (CST, #8457, D6A8, 1:5000 for western blots), Fibronectin (CST, #26836, E5H6X, 1:1000 for western blots, 1:200 for immunohistochemistry and

immunofluorescence), phosphor-AKT-Ser473 (CST, #9271, 1:1000 for western blots), AKT (CST, #9272, 1:1000 for western blots), phosphor-CREB-Ser133 (CST, #9198, 87G3, 1:1000 for western blots), CREB (CST, #9197, 48H2, 1:1000 for western blots), Phospho-GSK-3 β -Ser9 (CST, #5558, D85E12, 1:1000 for western blots), GSK-3 β (CST, #12456, D5C5Z, 1:1000 for western blots), and anti- α 5 integrin antibody (Sigma-Aldrich, MAB1956Z, P1D6). Anti- α V β 3 integrin antibody (LM609) was produced as previously described⁴⁹. Secondary antibodies for western blots include anti-rabbit IgG (CST, #7074, 1:3000 for western blots) and anti-mouse IgG (CST, #7076, 1:3000 for western blots).

Cell lines.

Pancreatic ductal adenocarcinoma cell lines (XPA1, MiaPACA-2) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). 79E and 34E cells were derived from patient-derived xenograft (PDX) models established by Dr. Andrew Lowy (University of California, San Diego). The fast-growing variant of the pancreatic carcinoma cell line Colo-357 was a gift from Dr. Shama Kajiji and Vito Quaranta (The Scripps Research Institute). Cells were grown in DMEM containing 10% FBS (Gibco) and 1% penicillin-streptomycin (Thermo Fisher Scientific, Waltham, MA) and cryopreserved as low-passage stocks. All cell lines were regularly tested for mycoplasma contamination using PCR mycoplasma detection kit (Genlantis, San Diego, CA). All cell lines were tested mycoplasma negative.

Genetic knockdown and ectopic expression.

Cells were transfected with vector control or *LPAR4* using a lentiviral system. Lentiviruses were produced in 293T cells co-transfected with lentiviral backbone constructs and packing vectors (ps-PAX2 and VSVG) using Lipofectamine 3000 (ThermoFisher Scientific). For knockdown experiments, cells were transfected with siRNA (Sigma-Aldrich) using the Lipofectamine RNAiMAX (Thermo Fisher Scientific) or with shRNA (Sigma-Aldrich) using a lentiviral system. Two siRNAs or shRNAs targeting different regions of the gene of interest were applied for the gene knockdown. Ectopic expression and knockdown effects were confirmed by qRT-PCR. miRNA inhibitor (Millipore Sigma) or mimic (Millipore Sigma) transfections were conducted using Lipofectamine RNAiMAX. Cells were harvested 48 hours post transfection for RNA isolation and qPCR analysis or for methylcellulose tumorsphere formation assay. Supplementary Table 5 shows details for constructs, siRNAs, and miRNA reagents.

Application of cellular stress in vitro.

Hypoxia: Cells at ~50% confluence were grown in a 1% O₂ hypoxia chamber (Coylab) or 21% O₂ normoxia chamber (regular tissue culture chamber) on 2D monolayer culture for 72 hours. Oxidative stress: 5 X10⁵ cells were seeded in a 12-well ultra-low attachment plate (Corning, 3D) and treated with different doses of H₂O₂ for 48 hours. Serum deprivation: 5 X10⁵ cells were seeded on 2D (6-well plate) or 12-well ultra-low attachment plate (Corning, 3D) in the presence of 10% regular FBS or 0% FBS- supplemented media for 48 hours. Medium were substituted with 10% regular FBS-supplemented media for both experimental and control cells for 2 hours prior to cell harvest. Chemotherapy stress: 5 X10⁵ cells were

seeded in 12-well ultra-low attachment plate a day before treatment of various doses of gemcitabine or paclitaxel for 24 hours.

Subcutaneous and orthotopic tumor studies.

Experiments were conducted under protocol S05018 approved by the UC San Diego Institutional Animal Care and Use Committee in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All experiments utilized 6-to-8-week-old female immune-compromised nu/nu mice (Charles River Labs, Wilmington, MA). Mice were kept on a 12-hour light/dark cycle, 7:00 to 18:00 at ambient room temperature of ~22 Celsius degree, and at humidity of 40–60%, monitored through the building control management system. The maximal tumor volume permitted by IACUC is $2 \times 10^3 \text{ mm}^3$ and was not exceeded.

A limiting dilution assay was used to estimate the frequency of tumor-initiating cells. Briefly, 1 million, 100K, 10K, 1K, 100, or 10 cells were suspended in a 1:1 mixture of Hanks Balanced Salt Solution and Phenol Red-free Basement Membrane Matrix (BD Biosciences, San Diego, CA) and injected subcutaneously. Mice were examined twice weekly for palpable tumors. The results were tabulated as the number of tumors observed (at the specified endpoint) per the number of tumors injected, and used to calculate the frequency of tumor-initiating cells using ELDA software⁵⁰.

Based on the limiting dilution experiments, the tumor take rate was about 50% for a 300-cell injection and 100% for 1 million cells. As such, we reasoned that tumor formed after injection of 300 cells are enriched for cancer stem or self-renewing cells. Mice received a subcutaneous injection of 300 or 1 million tumor cells to the flank and were checked twice weekly for palpable tumors. Once a tumor was observed, the tumor was harvested, cut bluntly into pieces and ground on ice using a glass tissue grinder with 20% Binding Buffer from the High Pure miRNA Isolation Kit (Roche) for tissue homogenization. Supernatants collected after tissue homogenization were utilized for total RNA isolation using the High Pure miRNA Isolation Kit (Roche), following the manufacturer's protocol.

For 300 cells injection xenograft model, +EV or +R4 cells were transfected with either FN1 siRNA or scrambled siRNA for 48 hours prior to harvest, then 300 cells mixed with Phenol Red-free Basement Membrane Matrix (1:1 ratio) were subcutaneously injected into mice. At day 20, the number of palpable tumors formed were counted.

For tumor initiation in an orthotopic model, Colo-357-sh-CTRL or sh-R4.1 cells were firstly transduced with luciferase lentivirus. Cells with equivalent levels of luciferase activity were implanted into the pancreas of nu/nu mice. Tumor initiation in the pancreas of mice was monitored twice a week by using non-invasive bioluminescence imaging. Note that all mice were imaged 10 minutes after injected with D-luciferin (L9504, Sigma-Aldrich). The frequency of tumor-initiating cells was analyzed using ELDA software⁵⁰.

Pancreatic cancer patient-derived xenograft study.

The study involving patient samples was following UCSD Institutional Review Board (IRB)-approved protocol (IRB number: 181755) and all patients were consented and not

compensated. The patients' information (sex and age) was blinded to protect patient confidentiality. The patient-derived xenografts mouse study was conducted under the protocol S09158 approved by the UC San Diego Institutional Animal Care and Use Committee in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Briefly, 1–2 mm³ PDX fragments (n=8 patient tumor samples) were implanted to pancreas of NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl}/SzJ (NSG) mice. Tumor growth was monitored by weekly ultrasound imaging. Once a tumor size reached 50–100 mm³, the mouse was recruited randomly and subsequently treated with vehicle or 100 mg/kg gemcitabine (intraperitoneal injection) twice a week for up to 6 weeks. Once the control tumor group reached a diameter of 2.0 cm³, all mice were sacrificed for tumor harvest and qPCR analysis.

Quantitative RT-PCR and RNA-Seq.

RNA was collected using the RNeasy RNA Purification kit (Qiagen, Germantown, MD). Cells were harvested at the indicated time points and conditions. Adherent (2D) cells were washed twice with 1X HBSS (Gibco, #14025076) and scraped off in the presence of Buffer RLT (Qiagen). Cells grown in ultra-low attachment plates (Corning, #3473) were harvested through centrifugation (300Xg, 5 minutes) and washed twice with 1X HBSS before lysing with Buffer RLT. cDNA was synthesized by using High-Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific), and RT-PCR was performed on a LightCycler with SYBR Green (BioRad, Irvine, CA). Expression of each target gene is normalized by comparing the target Ct value to the geometric mean of the Ct for the five housekeeping genes, *RPL37A*, *ACTB*, *TUBB*, *VCL* and *GAPDH*. Primer sequences are listed in Supplementary Table 6. For RNA-seq experiments, RNA was extracted using the RNeasy RNA Purification kit (Qiagen) following the manufacturer's instructions. A total of 1 µg RNA per sample was used to generate RNA-seq libraries using NEBNext Ultra RNA library prep kit (NEB, USA) following manufacturer's protocol. PCR products were purified (AMPure XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system. The clustering of the index-coded samples was performed on Illumina Novaseq sequencer according to the manufacturer's protocol. Subsequently, the RNA libraries were sequenced on Illumina Novaseq machine and paired-end reads were generated. The Python package HTSeq was used to generate read counts for each gene which were analyzed using the R package DESeq2 (v.1.28.0). Benjamini and Hochberg correction were used to calculate adjusted *P* values (p.adj) for differentially expressed genes. A p.adj < 0.01 was required to consider genes as differentially expressed ones. Heatmaps were generated using Java Treeview (v.1.1.6r4). Total RNA (including small RNA) was isolated using the High Pure miRNA Isolation Kit (Roche), following the manufacturer's protocol. cDNA for miRNA was synthesized and the stem-loop RT-PCR method was applied to assess the expression of miRNA of interest following the protocol described in detail by Xie et al⁵¹. PCR cycles for amplifying all miRNA were: Stage 1: 94°C, 3 minutes, 1 cycle; Stage 2: 95°C, 15 seconds; 60°C, 45 seconds; 45 cycles; Stage 3: Dissociation analysis. Expression of the target miRNA is normalized by comparing the target Ct value to the geometric mean of the Ct for the two housekeeping miRNAs, U6 and miR-16-5p. Primer sequences for miRNA expression are listed in Supplementary Table 6.

LPAR4–3'UTR luciferase reporter assay.

The LPAR4–3'UTR luciferase reporter plasmid (HmiT099310-MT05) and control plasmid (CmiT000001-MT05) were purchased from GeneCopoeia. Briefly, cells were transfected with LPAR4–3'UTR reporter plasmid or control plasmid using lipofectamine 3000 (ThermoFisher Scientific) at day 1, and at day 2 cells were subsequently transfected with 100 nM miR-139-mimic, or anti-miR, or scrambled control mimic, respectively, using lipofectamine RNAiMAX (ThermoFisher Scientific). At day 4, luciferase and Secreted alkaline phosphatase (SEAP) luciferase activities for each sample were accessed separately by using Secrete-Pair Dual Luminescence Assay Kit (LF031, GeneCopoeia).

Chromatin immunoprecipitation (ChIP)-qPCR assay.

The ChIP kit was purchased from Cell Signaling (SimpleChIP Plus Chromatin IP kit, #9005) and the experiments were performed according to the protocol provided by Cell Signaling Technology. Briefly, cells grew in charcoal stripped FBS containing media up to 90% confluence prior to crosslink using 37% formaldehyde for 10 minutes at room temperature. Nuclei/chromatin was digested and sonicated after 3 sets of 20-second pulse and 3 sets of 30-second on wet ice between pulses (Branson Digital Sonifier 450). Chromatin lysates were incubated with anti-CREB antibody (#4820, Cell Signaling) or anti-IgG (#2729, Cell Signaling) at 4°C with rotation overnight. The eluted DNA products were subsequently utilized for real-time qPCR assay. Primers for detecting FN1-exon1 are available in Supplementary Table 6. The details of the PCR reaction program are: initial denaturation: 95°C, 3 minutes; Denature: 95°C, 15 seconds; Anneal & Extension: 60°C, 60 seconds; Repeat step Denature and Anneal & Extension for a total of 40 cycles.

Western blots.

Western blots were performed as described previously⁴⁵. Briefly, cells were harvested at the mentioned time points and conditions. Adherent (2D) cells were washed three times with 1X HBSS and scraped off in the presence of 1X RIPA buffer containing protease and phosphatase inhibitors, or 2X Laemmli sample buffer containing reducing agent. Cells grown in suspension (3D) were harvested through centrifugation (300Xg, 5 minutes) and washed twice with 1X HBSS before lysing with cell lysis buffer mentioned above. BCA assay (Thermo Fisher Scientific) was performed, and lysates were normalized. Sample buffer containing reducing reagent were added to the 1X RIPA buffer lysate and then heated at 95°C for 5 minutes. 20 µg of protein was loaded on an SDS-PAGE gel. Blocking and probing were done in 5% fat-free milk + TBS-T buffer. ECL reagent (Thermo Fisher Scientific) was used to visualize protein bands.

Methylcellulose tumorsphere forming assay.

Methylcellulose tumorsphere forming assay was performed following manufacturer's instructions. Briefly, cells were washed with 1x HBSS and centrifuged at 300 X g for 5 minutes, and cell number was counted by the Trypan blue exclusion assay. Briefly, 4000 cells were mixed in 1mL methylcellulose stock media (HSC001, R&D systems, Minneapolis, MN) in 24-well non-treated plate (Corning), topped by 1 mL 10% regular FBS- or 10% charcoal stripped FBS-supplemented medium. After 12 days, one lower

magnification image of each well plus 3 random fields with higher magnification within each well were acquired using an AmScope microscope (MU1603). The number and % area of tumorspheres per field was computed using Image J (NIH, MD).

Flow cytometry detecting mitochondrial superoxide (MitoSOX).

MitoSOX Red (Thermo Fisher, M36008) staining was used according to the manufacturer's instructions. Briefly, 5×10^5 cells were seeded on 6-well tissue culture plate in serum-free media for 48 hours. Cells were washed with 1 X HBSS twice and were disassociated with 0.5% trypsin buffer, then washed with 1 X HBSS and centrifuged with $300 \times g$ for 5 minutes twice. Subsequently cells were stained with $5 \mu\text{M}$ MitoSOX reagent for 10 minutes at 37°C , protected from light, before flow cytometry analysis. An example of gating strategy for this assay is provided in Supplementary Figure. Data were analyzed with FlowJo.v10.

Immunohistochemistry staining.

Immunohistochemistry staining of LPAR4 or FN1 in human PDAC tissue array (US Biomax PA484a) or formalin-fixed, paraffin-embedded xenograft tumors were performed using the LPAR4 antibody (Thermo Fisher, #PA5-49727) or FN1 antibody (CST, #26836, E5H6X) following the manufacturer's protocol. Slides were later imaged on a NanoZoomer Slide Scanning System (Hamamatsu). The LPAR4 antibody was validated for immunohistochemistry application by the manufacturer, as well as in-house validation by staining orthotopic xenograft tumors generated by 79E+EV vs.79E+R4 cells (Extended Data Fig. 8).

Immunofluorescence staining.

Briefly, cells were grown on 8-well chamber slide (Nunc™ Lab-Tek™ chamber slide, Thermo Scientific) and fixed with 4% formaldehyde for 15 minutes at room temperature. Cells were then incubated with primary antibodies at a dilution of 1:1000 (anti-FN1) for overnight at 4°C , following by secondary antibody at a dilution of 1:2000 for 1 hour and DAPI staining for 5 minutes at room temperature. Images were acquired by Nikon Eclipse C1 confocal microscope and analyzed with NIS-Elements Viewer 5.21.


Production and testing of cell-free extracellular matrix.

+EV or +R4 cells were seeded confluent on 6- or 96-well tissue culture plate (Corning) in serum-free medium for 72 hours to deposit extracellular matrix (ECM). Cells were thereafter removed with 20% ammonium hydroxide solution following an established protocol⁵². For the cell growth assay, 1×10^5 cells were seeded on 6-well plate pre-coated with extracellular matrix derived from +EV (ECM-EV) or +R4 (ECM-R4) cells in the absence of serum up to 12 days. For H_2O_2 and gemcitabine resistance assay, 2×10^4 cells were seeded on 96-well plate pre-coated with ECM-EV, ECM-R4, or ECM-R4 with FN1 knockdown in the absence of serum. Next day, cells were treated with various doses of H_2O_2 or gemcitabine, or in combination with antibody P1D6 ($5 \mu\text{g}/\text{mL}$) or antibody LM609 ($5 \mu\text{g}/\text{mL}$) up to 72 hours. The number of viable cells were assessed by the CellTiter-Glo kit (Promega).

Statistical analysis.


Fisher’s exact tests, One-Way ANOVA tests or Student *t* tests were performed using Prism (GraphPad 9.4.1, San Diego, CA) and Microsoft Excel 365. *P*<0.05 was considered significant. Data distribution was assumed to be normal, but this was not formally tested. No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications^{53, 54}. No randomization was used except all the mice for the in vivo study were allocated randomized. Single-blinding was performed for all in vivo assays and data analysis, as well as for RNA-seq data analysis. Data collection and analysis were not performed blind to the in vitro experiments. No samples, mice or data points were excluded for analysis.

Extended Data




Extended Data Fig. 1: LPAR4 is a stress inducible gene.

a, Graph showing relative mRNA expression of six *LPARs* (normalized to housekeeping gene *RPL37A*) for cells grown in 10% serum and 2D. **b**, Graph comparing *LPARs* expression on cells grown in stem-like culture conditions (i.e., no serum/3D) for 72 hours with respect to cells grown in 10% serum on 2D for 72 hours. **c**, Graph comparing *LPARs* expression on cells grown in hypoxia condition (1% O₂) for 72 hours with respect to cells grown in normoxia for 72 hours. **d-e**, Graphs comparing *LPARs* expression on cells grown in 3D condition treated with varying doses of gemcitabine or paclitaxel for 24 hours. Bars represent median value per cell line (**a-c**). Data were presented as mean ± s.d. for n=3 independent experiments. Statistical analyses were performed using two tailed unpaired one sample t-test (**b-e**). Source numerical data are available in source data.




Extended Data Fig. 2: *LPAR4* does not impact cell growth in the absence of stress.

a, Immunohistochemistry staining of *LPAR4* in a PDAC tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μ M. Representative images showing normal pancreas (n=4 biological samples), low-*LPAR4* PDAC (n=9 biological samples), and high-*LPAR4* PDAC (n=6 biological samples). Bar graph shows the relative percentage of *LPAR4*-low and *LPAR4*-high patients in the PDAC tissue array. **b**, Quantitative RT-PCR confirming the manipulation of *LPAR4* expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean \pm s.d. (n=4 independent experiments for Colo-357 and 79E cells with *LPAR4* stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with *LPAR4* ectopic expression, n=3 for 34E cells with *LPAR4* stable knockdown, and n=4 for 34E with *LPAR4* ectopic expression). **c**, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+Luciferase or Colo-357+sh-R4.1+Luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. **d, f**, Trypan blue exclusion assay showing the relative number of viable cells with or without *LPAR4* expression manipulation grown in 10% serum and 2D at day 4 and day 7. **e**, Tumor growth rates for 1 million Colo-357 cells with or without *LPAR4* expression manipulation in a subcutaneous tumor model. Data were presented as mean \pm s.d. for n=8 independent samples for each group. **g**, Quantitative RT-PCR confirming the knockdown of *LPAR1* in Colo-357 cells. **h**, Effects of *LPAR1* knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean \pm s.d. for n=3 independent experiments (**d,f,g**, and **h**). Statistical analyses were performed using two tailed unpaired one sample t-test (**b,g**, and **h**) and one-way ANOVA (**d-f**). Source numerical data are available in source data.




Extended Data Fig. 3: miR-139-5p downregulates LPAR4 expression in pancreatic cancer cells.

a, Graphs showing the log₂-FC of miR-139-5p expression level in cells with or without *LPAR4* expression manipulation. **b**, Graph shows the log₂-FC of mRNA level of *LPARs* in Colo-357 cells treated with anti-miR-139-5p, normalized to cells treated with scrambled control miRNA. Data were presented as mean ± s.d. for n=6 independent experiments for *LPAR4* and n=5 for other *LPARs*. **c**, Construct map for *LPAR4*-3'UTR luciferase reporter vector or control vector. **d**, Immunoblots showing representative of three independent experiments for *LPAR4* protein level in Colo-357-sh-CTRL or sh-R4.1 cells treated with scrambled control miRNA vs. anti-miR-139-5p. **e**, Graphs showing the log₂-FC of mRNA level of *LPAR4* and various predicated miR-139-5p targets in Colo-357 or 34E cells treated with miR-139-5p mimic, normalized to cells treated with scrambled control miRNA. Data were presented as mean ± s.d. for n=3 independent experiments (**a**, **b**, and **e**). Statistical analyses were performed using two tailed unpaired one sample t-test (**a**, **b**, and **e**). Source numerical data are available in source data.




Extended Data Fig. 4: LPAR4 upregulates ECM genes and cancer stemness-related genes in the absence of exogenous LPA.

a, Quantitative RT-PCR confirmation of LPAR4 regulated genes associated with ECM in two additional pairs of +EV vs. +R4 cells, grown in charcoal stripped FBS containing media. All mRNA level was normalized to +EV cells. **b**, Graphs showing the relative number of viable 79E+EV or 79E+R4 cells treated with various doses of H₂O₂ or gemcitabine in serum-free media for 72 hours, evaluated by the CellTiter-Glo assay. **c**, Graph showing the number of tumorspheres formed by Colo-34+EV or Colo-357+R4 cells grown in 3D suspension with serum-free media at day 10. The right panel shows representative images from three biological experiments for spheres formed by +EV or +R4 cells at day 10. **d**, Relative gene expression of CSC markers and antioxidant genes in +EV vs. +R4 cells grown in charcoal stripped FBS containing media. All mRNA level was normalized to +EV cells. Data were presented as mean ± s.d. for n=3 independent experiments (**a-d**). Statistical analyses were performed using two tailed unpaired one sample t-test (**a, c, and d**). Source numerical data are available in source data.



Extended Data Fig. 5: *LPAR4* induces expression of FN1 isoforms containing EDA and EDB domains.


a, TNMplot showing *FN1* gene expression is significantly higher in pancreatic adenocarcinoma (PAAD) than in normal pancreas ($P < 0.0001$). The unpaired two-tailed t test was used for statistical analysis. Bars represent median values for each group. **b**, Graphs showing the relative mRNA level of total *FN1*, *FN1* containing EDA domain (*FN1-EDA*), and *FN1* containing EDB (*FN1-EDB*) in +EV vs. +R4 cells as indicated. All mRNA expression was normalized to +EV cells. Expression of *FN1-EDA* or *FN1-EDB* is quantitated independently by using two different sets of primers. **c**, Graphs showing the relative *LPAR4* mRNA level in cells stably transfected with scrambled shRNA (sh-CTRL) or two different *LPAR4* shRNAs (sh-R4.1 and sh-R4.2), treated with hypoxia and no serum for 72 hours. All were normalized to *LPAR4* mRNA level in normoxia and no serum condition. Data were presented as mean \pm s.d. for n=3 biological experiments (**b** and **c**). *P*-value was calculated using two tailed unpaired one sample t-test. Source numerical data are available in source data.



Extended Data Fig. 6: FNI is a critical mediator of LPAR4-induced cancer stemness.

a, Gene Set Enrichment Analysis (GSEA) for LPAR4-induced gene expression suggests that AKT signaling is upregulated in 79E+R4 cells in the absence of LPA. **b**, Immunoblot showing representative of three biological experiments for the protein levels of p-AKT-S473, AKT, p-GSK-3 β -S9, p-CREB-S133, CREB, and vinculin in Colo-357+EV and Colo-357+R4 cells treated with Ipatasertib of a range of doses for 2 hours, or with 1 μ M Ipatasertib in a time-course experiment. **c**, Relative mRNA level of ECM-related genes among LPAR4 gene signature in +R4 cells transfected with si-CREB as compared to cells transfected with si-CTRL. **d**, Graphs showing the cell viability of cells grown on 2D with serum free or with 10% charcoal stripped FBS containing media. Cell viability was assessed


by the CellTiter-Glo assay, and all numbers were normalized to EV cells transfected with si-CTRL. **e**, Quantitative RT-PCR confirmation of *FN1* knockdown by using siRNA in three pairs of +EV and +R4 cells as indicated. **f**, Representative histograms of three biological experiments showing MitoSOX signaling in +EV vs. +R4 cells treated with scrambled siRNA or si-FN1. All cells were cultured in serum free media for 48 hours prior to MitoSOX staining. Data were presented as mean \pm s.d. for n=3 biological experiments (**c-e**). *P*-value was calculated using two tailed unpaired one sample t-test. Source numerical data are available in source data.



Extended Data Fig. 7: ECM deposited by LPAR4+ cells endows LPAR4-negative cells with growth advantage.

a, Representative images for three biological experiments for Colo-357 cells grown on uncoated plate or on plate coated with extracellular matrix deposited by 79E+EV or 79E+R4 cells in serum-free media at day 1, day 2, day 7, and day 12. Scale bar = 50 μ m. Yellow color circled areas show representative cell colony.

In-house LPAR4 antibody validation



Extended Data Fig. 8: Validation of LPAR4 antibody for immunohistochemistry application.

Representative LPAR4 immunohistochemistry staining for orthotopic xenograft tumors from 79E+EV (n=3 biologically independent samples) and 79E+R4 (n=3 biologically independent samples).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Alex Reiss, Molly Morgan, and Mahima Advani for their technical support. This study was funded by the University of California Tobacco-Related Disease Research Program (CW, T29FT0343), and from grants awarded by the NIH, including T32CA009523 (TR), T32OD017863 (HIW), T32HL086344 (HIW), K01OD030513 (HIW), R01CA155620 (AML), R01CA045726 (DAC), and R35CA220512 (DAC). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Data availability

RNA-seq data that support the findings of this study have been deposited in the Gene Expressing Omnibus (GEO) under accession code GSE198002.

The human pancreatic adenocarcinoma data were derived from the TCGA Research Network: <http://cancergenome.nih.gov/> and <http://www.cbioportal.org/>. The TNMplot public dataset that supports the findings of this study is available in <https://tnmplot.com/analysis/> or details of source data files.

All other data supporting the findings of this study are available from the corresponding author on reasonable request.

References

1. Clarke MF Clinical and Therapeutic Implications of Cancer Stem Cells. *N Engl J Med* 380, 2237–2245 (2019). [PubMed: 31167052]
2. Zhou P et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. *Mol Cancer* 16, 52 (2017). [PubMed: 28245823]
3. Plaks V, Kong N & Werb Z The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? *Cell Stem Cell* 16, 225–238 (2015). [PubMed: 25748930]
4. Delmore JE et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell* 146, 904–917 (2011). [PubMed: 21889194]
5. Tigyi G, Lin KH, Jang IH & Lee SC Revisiting the role of lysophosphatidic acid in stem cell biology. *Exp Biol Med* (Maywood) 246, 1802–1809 (2021). [PubMed: 34038224]
6. Seo EJ et al. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism. *Stem cells* 34, 551–564 (2016). [PubMed: 26800320]
7. Hung KF, Yang T & Kao SY Cancer stem cell theory: Are we moving past the mist? *J Chin Med Assoc* 82, 814–818 (2019). [PubMed: 31469690]
8. Senft D & Ronai ZE Adaptive Stress Responses During Tumor Metastasis and Dormancy. *Trends Cancer* 2, 429–442 (2016).
9. Hayes JD, Dinkova-Kostova AT & Tew KD Oxidative Stress in Cancer. *Cancer cell* 38, 167–197 (2020). [PubMed: 32649885]
10. Yao W, Maitra A & Ying H Recent insights into the biology of pancreatic cancer. *EBioMedicine* 53, 102655 (2020). [PubMed: 32139179]

11. Chen J, Li H, Xu W & Guo X Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer. *BMC Gastroenterol* 21, 58 (2021). [PubMed: 33568105]
12. Auciello FR et al. A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. *Cancer Discovery*, CD-18–1212 (2019).
13. Juin A et al. N-WASP Control of LPAR1 Trafficking Establishes Response to Self-Generated LPA Gradients to Promote Pancreatic Cancer Cell Metastasis. *Developmental cell* 51, 431–445 e437 (2019). [PubMed: 31668663]
14. Yamada T et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. *The Journal of biological chemistry* 279, 6595–6605 (2004). [PubMed: 14660630]
15. Komachi M et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. *Carcinogenesis* 30, 457–465 (2009). [PubMed: 19129242]
16. Ishii S et al. Diverse effects of LPA4, LPA5 and LPA6 on the activation of tumor progression in pancreatic cancer cells. *Biochemical and biophysical research communications* 461, 59–64 (2015). [PubMed: 25849892]
17. Lee JW et al. Lysophosphatidic Acid Receptor 4 Is Transiently Expressed during Cardiac Differentiation and Critical for Repair of the Damaged Heart. *Mol Ther* 29, 1151–1163 (2021). [PubMed: 33160074]
18. Auciello FR et al. A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression. *Cancer discovery* 9, 617–627 (2019). [PubMed: 30837243]
19. Bartha A & Györfy B TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. *Int J Mol Sci* 22 (2021).
20. Sen CK & Ghatak S miRNA control of tissue repair and regeneration. *Am J Pathol* 185, 2629–2640 (2015). [PubMed: 26056933]
21. Chaudhary AK, Mondal G, Kumar V, Kattel K & Mahato RI Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. *Cancer Lett* 402, 1–8 (2017). [PubMed: 28536008]
22. Jiao X et al. microRNA: The Impact on Cancer Stemness and Therapeutic Resistance. *Cells* 9 (2019).
23. Ma J, Zhang J, Weng YC & Wang JC EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer. *Mol Cells* 41, 868–880 (2018). [PubMed: 30304920]
24. Houssein LK et al. miR-139 impacts FoxO1 action by decreasing FoxO1 protein in mouse hepatocytes. *Biochemical and biophysical research communications* 390, 1278–1282 (2009). [PubMed: 19883627]
25. Okoye I et al. Plasma Extracellular Vesicles Enhance HIV-1 Infection of Activated CD4(+) T Cells and Promote the Activation of Latently Infected J-Lat10.6 Cells via miR-139-5p Transfer. *Front Immunol* 12, 697604 (2021). [PubMed: 34249000]
26. Topalovski M & Brekken RA Matrix control of pancreatic cancer: New insights into fibronectin signaling. *Cancer letters* 381, 252–258 (2016). [PubMed: 26742464]
27. Magnuson MA & Osipovich AB Pancreas-specific Cre driver lines and considerations for their prudent use. *Cell metabolism* 18, 9–20 (2013). [PubMed: 23823474]
28. Geraldo LHM et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. *Signal Transduct Target Ther* 6, 45 (2021). [PubMed: 33526777]
29. Winkler J, Abisoye-Ogunniyan A, Metcalf KJ & Werb Z Concepts of extracellular matrix remodelling in tumour progression and metastasis. *Nature communications* 11, 5120 (2020).
30. Ou J et al. Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. *Stem cell research* 11, 820–833 (2013). [PubMed: 23811539]
31. Yu Q et al. Fibronectin Promotes the Malignancy of Glioma Stem-Like Cells Via Modulation of Cell Adhesion, Differentiation, Proliferation and Chemoresistance. *Front Mol Neurosci* 11, 130 (2018). [PubMed: 29706869]

32. Zhong C et al. Remodeling cancer stemness by collagen/fibronectin via the AKT and CDC42 signaling pathway crosstalk in glioma. *Theranostics* 11, 1991–2005 (2021). [PubMed: 33408794]
33. Efthymiou G et al. Shaping Up the Tumor Microenvironment With Cellular Fibronectin. *Frontiers in oncology* 10, 641 (2020). [PubMed: 32426283]
34. Nakayama K cAMP-response element-binding protein (CREB) and NF-kappaB transcription factors are activated during prolonged hypoxia and cooperatively regulate the induction of matrix metalloproteinase MMP1. *The Journal of biological chemistry* 288, 22584–22595 (2013). [PubMed: 23775082]
35. Habib SL, Mohan S, Liang S, Li B & Yadav M Novel mechanism of transcriptional regulation of cell matrix protein through CREB. *Cell Cycle* 14, 2598–2608 (2015). [PubMed: 26115221]
36. Sakamoto KM & Frank DA CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research* 15, 2583–2587 (2009). [PubMed: 19351775]
37. Singh P & Schwarzbauer JE Fibronectin and stem cell differentiation - lessons from chondrogenesis. *J Cell Sci* 125, 3703–3712 (2012). [PubMed: 22976308]
38. Gattazzo F, Urciuolo A & Bonaldo P Extracellular matrix: a dynamic microenvironment for stem cell niche. *Biochimica et biophysica acta* 1840, 2506–2519 (2014). [PubMed: 24418517]
39. Topalovski M & Brekken RA Matrix control of pancreatic cancer: New insights into fibronectin signaling. *Cancer Lett* 381, 252–258 (2016). [PubMed: 26742464]
40. Amrutkar M, Aasrum M, Verbeke CS & Gladhaug IP Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. *BMC Cancer* 19, 596 (2019). [PubMed: 31208372]
41. Feig C et al. The pancreas cancer microenvironment. *Clinical cancer research : an official journal of the American Association for Cancer Research* 18, 4266–4276 (2012). [PubMed: 22896693]
42. Liu X, Zhou L, Chen Y, Jiang X & Jiang J CircRNF13 Promotes the Malignant Progression of Pancreatic Cancer through Targeting miR-139-5p/IGF1R Axis. *J Oncol* 2021, 6945046 (2021). [PubMed: 34899908]
43. Bao B, Yu X & Zheng W MiR-139-5p Targeting CCNB1 Modulates Proliferation, Migration, Invasion and Cell Cycle in Lung Adenocarcinoma. *Mol Biotechnol* 64, 852–860 (2022). [PubMed: 35181869]
44. Jin SS, Lin CJ, Lin XF, Zheng JZ & Guan HQ Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway. *Ann Hepatol* 27, 100584 (2022). [PubMed: 34808393]
45. Seguin L et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. *Nature cell biology* 16, 457–468 (2014). [PubMed: 24747441]
46. Desgrosellier JS et al. Integrin alphavbeta3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. *Developmental cell* 30, 295–308 (2014). [PubMed: 25117682]
47. Desgrosellier JS et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. *Nature medicine* 15, 1163–1169 (2009).
48. Sun Q et al. Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. *The Journal of clinical investigation* 128, 531–544 (2018). [PubMed: 29227280]
49. Cheresh DA & Spiro RC Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. *The Journal of biological chemistry* 262, 17703–17711 (1987). [PubMed: 2447074]
50. Hu Y & Smyth GK ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. *J Immunol Methods* 347, 70–78 (2009). [PubMed: 19567251]
51. Xie S et al. sRNAPrimerDB: comprehensive primer design and search web service for small non-coding RNAs. *Bioinformatics* 35, 1566–1572 (2019). [PubMed: 30295699]
52. Hellewell AL, Rosini S & Adams JC A Rapid, Scalable Method for the Isolation, Functional Study, and Analysis of Cell-derived Extracellular Matrix. *Journal of visualized experiments : JoVE* (2017).

53. Seguin L et al. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. *Cancer discovery* 7, 1464–1479 (2017). [PubMed: 28893801]
54. Cosset E et al. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. *Cancer cell* 32, 856–868 e855 (2017). [PubMed: 29198914]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 1: Pancreatic cancer cells selectively upregulate LPAR4 in response to isolation stress.
a, Log₂ fold change (log₂-FC) for all *LPARs* mRNA expression in “self-renewing” tumors formed by subcutaneous injection of 300 cells of Colo-357 (pink dots, n=6 biologically independent samples), 79E (black dots, n=4 biologically independent samples), or 34E (blue dots, n=6 biologically independent samples) with respect to “bulk” tumors formed by injection of 1 million cells of Colo-357 (n=6 biologically independent samples), 79E (n=6 biologically independent samples), or 34E (n=5 biologically independent samples).
b, Representative images of immunohistochemistry staining of LPAR4 in 79E xenograft tumors derived from 1M cells (n=5 biologically independent samples) or 300 cells (n=4 biologically independent samples). Scale bar is 50 µm or 10 µm as indicated.
c, Relative *LPAR4* mRNA level (normalized to housekeeping genes) in xenograft tumors harvested at early time point (day 20, early lesions,) vs. late time point (day 35, established tumors,).
d, Log₂ fold change (log₂-FC) for all *LPARs* mRNA expression in “self-renewing” tumors formed by subcutaneous injection of 300 cells of Colo-357 (pink dots, n=6 biologically independent samples), 79E (black dots, n=4 biologically independent samples), or 34E (blue dots, n=6 biologically independent samples) with respect to “bulk” tumors formed by injection of 1 million cells of Colo-357 (n=6 biologically independent samples), 79E (n=6 biologically independent samples), or 34E (n=5 biologically independent samples).
e, Bar graphs showing LPAR4 mRNA levels (log₂-FC normalized to control) in response to Gemcitabine treatment (20, 30, 10, 30, 50, 100 nM) in Colo-357, 79E, and 34E cell lines. P-values are indicated above each bar.
f, Bar graphs showing LPAR4 mRNA levels (log₂-FC normalized to control) in response to Paclitaxel treatment (30, 60, 25, 50, 25, 75 nM) in Colo-357, 79E, and 34E cell lines. P-values are indicated above each bar.
g, Western blots showing LPAR4 and Vinculin protein levels in Colo-357, 79E, and 34E cells under various stress conditions: Hypoxia (72hrs), No serum (72hrs), Oxidative stress (3D, 48hrs), and Gemcitabine (3D, 24hrs). Vinculin is used as a loading control. Molecular weights are indicated in kDa.
h, Orthotopic PDX tumor model. 1-2mm³ PDX fragments were implanted into the pancreas of NSG mice. Tumor growth was monitored by ultrasound until reaching 50-100mm³. Mice were then treated twice weekly intraperitoneally with either vehicle or 100 mg/kg Gemcitabine for 6 weeks. Bar graph shows LPAR4 mRNA levels (2^{-ΔΔCT}) in orthotopic PDX tumors from vehicle (○) and Gemcitabine (●) treated mice. P=0.04.

Data are mean \pm s.d. (n=3, 4, 3 biologically independent samples from early lesions for Colo-357, 79E, 34E cells, respectively; n=4 biologically independent samples from established tumors for all three cell lines). **d**, All *LPARs* mRNA expression in cells grown as secondary tumorspheres with respect to cells grown in 10% serum on 2D (n=3 independent experiments for each line). **e-f**, *LPAR4* mRNA level in cells treated with various doses of gemcitabine or paclitaxel, relative to cells treated with vehicle control. Data are mean \pm s.d. (n = 3 independent experiments). **g**, *LPAR4* protein expression in cells treated with different stress as indicated. Data are representative of three independent experiments. **h**, Experimental flow showing the procedure of patient-derived xenograft (PDX) implantation to the pancreas of NSG mice following by treatment with vehicle or gemcitabine in vivo up to 6 weeks. Bar graph showing relative *LPAR4* mRNA expression in PDXs treated with vehicle or gemcitabine. Data are mean \pm s.d.(n=3 biologically independent samples for vehicle control and n= 5 for gemcitabine treated group). Bars represent median value per cell line (**a** and **d**). Statistical analyses were performed using two tailed unpaired one sample t-test (**a**, **c-f**, and **h**). Source numerical data and unprocessed blots are available in source data.




Fig. 2: *LPAR4* expression in patients with pancreatic cancer and its link to tumor initiation. **a**, TNMplot showing *LPAR4* gene expression in pancreatic adenocarcinoma (PAAD) and normal pancreas. Bars represent median value for each group. **b**, Relapse-free and overall survival for patients with low vs. high *LPAR4* expression in the TCGA PAAD dataset. **c**, In a subcutaneous tumor model, tumor initiating cells frequency (TIC) (95% interval) between control cells and *LPAR4* expression manipulated cells was calculated using ELDA software. P-values were obtained by Pearson's chi-squared two-tailed test. **d**, In an orthotopic tumor model, tumor initiating cells frequency (TIC) (95% interval) between Colo-357-sh-CTRL+luciferase cells and Colo-357-sh-R4.1+luciferase cells was calculated using ELDA

software. P-values were obtained by Pearson's chi-squared two-tailed test. **e**, Effect of ectopic *LPAR4* expression on tumorsphere formation for cells grown in methylcellulose media, plotted as fold change relative to cells expressing the empty vector control. Data are mean \pm s.d. (n=3, 4, 5 independent experiments for MiaPaCa2, Colo-357, and 79E cells, respectively). **f**, Fold change for the number of colonies for each group relative to control (no stress). Data are mean \pm s.d. (n=5 independent experiments for 79E treated with H₂O₂ and n=4 for 79E cells treated with serum deprivation, n=3 independent experiments for both Colo-357 and 34E cells). **g**, Median fluorescence intensities (MFI) of MitoSOX signaling in +EV or +R4 cells grown in serum-free media for 48 hours. Data are mean \pm s.d. (n = 3 independent experiments). **h**, Relative MFI of MitoSOX signaling in 79E cells stably transfected with sh-CTRL, sh-R4.1, or sh-R4.2 cultured in serum-free media for 48 hours. Data are mean \pm s.d. (n = 3 independent experiments). Statistical analyses were performed using two tailed unpaired one sample t-test. Source numerical data are available in source data.




Fig. 3: Stress suppresses miR-139-5p to release the brake on *LPAR4* expression.
a, Overall survival probability for high vs. low miR-139-5p for the TCGA PAAD dataset. **b**, Eight oligonucleotides are paired between *LPAR4* 3'UTR and hsa-miR-139-5p. **c**, Relative mRNA levels of *LPAR4*, miR-139-5p, and miR-138-5p in Colo-357 cells treated with serum deprivation stress (n= 3 independent experiments), hypoxia (n=3 independent experiments except n=2 for miR-138-5p), or oxidative stress (n= 4 independent experiments), normalized to cells treated with no stress. **d**, Relative mRNA levels of miR-139-5p and miR-138-5p in secondary methylcellulose spheres grown from Colo-357 or 34E cells as compared to their expressions in cells grown on 2D. **e**, Relative mRNA level of *LPAR4* in Colo-357 (n=7 independent experiments) or 79E cell lines (n=4 independent experiments) treated

with scrambled control miRNA or miR-139-5p mimic in normoxia vs. hypoxia. **f**, LPAR4 protein level in three cell lines treated with scrambled control miRNA or miR-139-5p mimic in normoxia vs. hypoxia. Data are representative of three independent experiments. **g**, The mRNA level of *LPARs* and *FOXO1* in 34E cells treated with miR-139-5p inhibitor relative to cells treated with scrambled control (n=3 independent experiments). **h**, The relative luciferase values in 34E (n=3 independent experiments) or Colo-357 (n=4 independent experiments) treated with miR-139-5p mimic or anti-miR-139-5p, along with their scrambled controls. **i**, Impact of miR-139-5p inhibitor on the mRNA level of *LPAR4* and the number of tumorspheres in Colo-357 cells with or without *LPAR4* knockdown (n=3 independent experiments for tumorsphere assay and n=4 for quantitative RT-PCR assay). **j**, Impact of miR-139-5p mimic on the mRNA level of *LPAR4* and on the number of tumorspheres in Colo-357 cells with or without *LPAR4* ectopic expression (n=3 independent experiments for tumorsphere assay and n=5 for quantitative RT-PCR assay). Data are presented as mean \pm s.d. in **c-e** and **g-i**. Statistical analyses were performed using two tailed unpaired one sample t-test (**c-e** and **g-j**). Source numerical data and unprocessed blots are available in source data.




Fig. 4: Differentially expressed genes common to *LPAR4*-expressing cells and patient tumors include extracellular matrix related genes.

a, Vector control (+EV) cells and *LPAR4* (+R4) cells were treated with or without 1 μM LPA for 2 hours. Samples were analyzed by RNA-seq and DESeq2 differential expression analysis was performed. Unsupervised clustering analysis reveals unique sets of differentially expressed genes (DEGs) associated with LPA treatment and *LPAR4* expression. Top gene ontology (GO) terms illustrate LPA-induced or *LPAR4*-induced effect on gene expression. **b**, Quantitative RT-PCR confirmation of *LPAR4* regulated genes associated with ECM in two pairs of +EV vs. +R4 cells, grown in charcoal stripped FBS containing media. All mRNA level was normalized to +EV cells. **c**, Overlap analysis was performed to identify DEGs that are commonly upregulated or downregulated for 79E+R4 cells and *LPAR4*-high tumors from the TCGA PAAD dataset. Full list of DEGs that overlap

between 79E+R4 cells and TCGA R4-high tumors are shown in Supplementary Table 4. **d**, Graphs showing IC50 values for H₂O₂ or Gemcitabine between 79E+EV and 79E+R4 cells, presented as mean± s.d. (n=3 biologically independent experiments), calculated by GraphPad Prime 9. **e**, Effect of ectopic *LPAR4* expression on tumorsphere formation for cells grown in methylcellulose media topped with charcoal stripped FBS containing media, plotted as fold change relative to cells expressing the empty vector control. Data were presented as mean ± s.d. (n=4 independent experiments for 79E cells and n=5 for both Colo-357 and MiaPaCa2). Statistical analyses were performed using two tailed unpaired one sample t-test (**b** and **d-e**). Source numerical data are available in source data.




Fig. 5: *LPAR4* expression promotes the cell-autonomous production of FN1.

a. Expression correlation between *LPAR4* and *FN1* from the TCGA PAAD dataset (n=177 samples). Pearson correlation coefficient $r=0.63$ and two-tailed $P<0.0001$. **b.** Expression correlation between *LPAR4* and *FN1* from the PDX tumors from the orthotopic mouse models treated with vehicle control (n=3 biologically independent samples) or gemcitabine (n=5 biologically independent samples). Pearson correlation coefficient $r=0.80$ and two-tailed $P=0.018$. **c.** Overall and relapse-free survival for patients with low vs. high FN1 expression in the TCGA PAAD dataset. **d.** Representative images for human FN1 immunohistochemistry staining in 79E (n=10 biologically independent samples), Colo-357 (n=4 biologically independent samples), or 34E (n=5 biologically independent samples) xenograft tumors formed from 1 million (1M) cells injected or 300 cells injected. Scale

bar is 50 μm . **e-f**, Western blot and immunostaining showing FN1 protein expression for pancreatic cancer cells with stable ectopic expression of *LPAR4* (+R4) vs. empty vector control (+EV) grown in charcoal striped FBS containing media for 72 hours. Data are representative of three biological experiments. **g**, Representative images for human FN1 immunohistochemistry staining in Colo-357+EV vs. Colo-357+R4 tumors harvested at day 15 post implantation in the pancreas of nu/nu mice. Images in the lower panel highlight FN1 staining in matrix areas. Data are representative of three biological samples. Scale bar is 100 μm or 20 μm as indicated. **h**, Effects of hypoxia and *LPAR4* knockdown on FN1 protein expression. Data are representative of three biological experiments. Source numerical data and unprocessed blots are available in source data.




Fig. 6: FN1, induced by the LPAR4/AKT/CREB signaling, is indispensable for LPAR4-induced TIC properties.

a, Effects of hypoxia and *LPAR4* knockdown on protein expressions of FN1, phosphorylated CREB at serine133 (p-CREB-S133), and CREB. **b**, Protein levels of p-CREB-S133, CREB, p-AKT-S473, AKT, and vinculin in +EV vs. +R4 cells, cultured in charcoal stripped FBS containing media for 72 hours. **c-d**, Effects of CREB inhibition by using siRNA knockdown or 666–15 on the protein levels of FN1, p-CREB-S133, and CREB in 34E+EV vs. 34E+R4 cells cultured in charcoal stripped FBS containing media for 72 hours. **e**, ChIP-qPCR assay showing CREB binding occupancy on *FN1* exon1 in +EV vs. +R4 cells cultured in charcoal stripped FBS containing media and IgG antibody serves as a negative control. The ChIP-qPCR signal was normalized to 2% input. **f**, Effect of AKT knockdown by using siRNA on FN1 protein expression in +EV vs. +R4 cells cultured in charcoal stripped FBS containing

media. **g**, Effects of AKT inhibition by Ipatasertib for 72 hours on the protein levels of FN1, AKT, p-GSK-3 β -S9, GSK-3 β , p-CREB-S133, and CREB in 34E+EV vs. 34E+R4 cells cultured in charcoal stripped FBS containing media. **h**, Relative number of tumorsphere formed by cells transfected with scrambled siRNA (si-CTRL) or FN1 siRNA (si-FN1) in methylcellulose media topped with 10% charcoal stripped FBS containing media. All numbers were normalized to EV cells transfected with si-CTRL. **i**, Median fluorescence intensity (MFI) of MitoSOX in +EV and +R4 cells transfected with si-CTRL or si-FN1, grown in serum-free media for 48 hours. **j**, Relative number of tumorsphere formed by cells transfected with empty vector (*EV*) or *FN1-EDA* in methylcellulose media topped with 10% FBS containing media. Immunoblots represent two independent experiments for FN1 protein expression in cells transfected with *EV* or *FN1-EDA* at day 3. Western blots shown in **a-d,f**, and **g** represents three biologically independent experiments. Data were presented as mean \pm s.d. in **e**, and **h-j** (n=3 independent experiments for **e, j**; n=5 for **h**, n=4 for Colo-357 cells and n=3 for 34E cells for **i**). Statistical analyses were performed using two tailed unpaired one sample t-test (**e**, and **h-j**). Source numerical data and unprocessed blots are available in source data.




Fig. 7: Extracellular matrix deposited by *LPAR4*-positive cells endows stemness features to *LPAR4*-negative cells in a FN1-dependent manner.

a, Experimental flow showing that +EV or +R4 cells were grown on tissue culture plastic for 72 hours in serum-free medium before cells were removed, and *LPAR4*-negative cells were plated atop the residual matrix in serum-free media. *LPAR4*-negative cells plated on uncoated tissue culture plate were used as baseline controls in this assay. **b-c**, Graph showing the number of viable cells, relative to baseline controls, assessed by the CellTiter-Glo assay. Data were presented as mean \pm s.d. for $n=3$ independent experiments for Colo-357 and $n=4$ independent experiments for 34E cells. **c**, represents three independent experiments for pictures of colonies formed at day 12. **d-e**, Graphs showing IC50 values for 79E cells grown on the matrix deposited by 79E+EV cells or 79E+R4 cells with vs. without *FN1* knockdown as indicated and then exposed to various doses of H_2O_2 or gemcitabine, or in combination with 5 μ g/mL anti- $\alpha 5$ antibody P1D6, or with 5 μ g/mL

anti- α V β 3 antibody LM609. Cell viability was assessed by the Cell-Titer Glo assay and IC50 values were calculated by GraphPad prism 9. Data were presented as mean \pm s.d. for n=4 independent experiments for **d** and n=3 independent experiments for **e**, **f**. The diagram shows 300 cells transfected with either scrambled siRNA (si-CTRL) or FN1 siRNA (si-FN1) were injected in a nu/nu mouse subcutaneously at four different sites. Graph showing the tumor take rate per mouse (n=5) for the four treatment groups analyzed at day 20. **g**, Schematic model of LPAR4 in pancreatic cancer. “Isolation stress” ① downregulates the expression of miR-139-5p ② that releases a brake on *LPAR4* expression ③ ④. Even the microenvironmental LPA is absent, LPAR4 is sufficient to activate AKT/CREB signaling ⑤, driving the expression of ECM related genes, including *FN1* ⑥. The deposited FN1 matrix protein ligates with its cell surface integrins α 5 β 1 and/or α V β 3 ⑦, endowing cells with several self-sufficient traits, including 3D growth and stress tolerance, ultimately promoting tumor initiation and cancer stemness ⑧. Statistical analyses were performed using two tailed unpaired one sample t-test (**b** and **d-f**). Source numerical data are available in source data.